BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25721699)

  • 1. The serum estradiol concentration is the main determinant of the estradiol concentration in normal breast tissue.
    Depypere HT; Bolca S; Bracke M; Delanghe J; Comhaire F; Blondeel P
    Maturitas; 2015 May; 81(1):42-5. PubMed ID: 25721699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
    Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
    Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and nontreated breast cancer patients.
    Cohen I; Figer A; Tepper R; Shapira J; Altaras MM; Yigael D; Beyth Y
    Gynecol Oncol; 1999 Feb; 72(2):202-7. PubMed ID: 10021302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fracture incidence in pre- and postmenopausal women after completion of adjuvant hormonal therapy for breast cancer.
    Koopal C; Janssen-Heijnen ML; van de Wouw AJ; van den Bergh JP
    Breast; 2015 Apr; 24(2):153-8. PubMed ID: 25618224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.
    Baumgart J; Nilsson K; Stavreus Evers A; Kunovac Kallak T; Kushnir MM; Bergquist J; Sundström Poromaa I
    Climacteric; 2014 Feb; 17(1):48-54. PubMed ID: 23647561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications].
    Petráková K; Krásenská M; Valík D; Holánek M; Palácová M; Demlová R
    Klin Onkol; 2016; 29 Suppl 3():S50-57. PubMed ID: 28118724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher than expected estradiol levels in aromatase inhibitor-treated, postmenopausal breast cancer patients.
    Kunovac Kallak T; Baumgart J; Stavreus Evers A; Sundström Poromaa I; Moby L; Kask K; Norjavaara E; Kushnir MM; Bergquist J; Nilsson K
    Climacteric; 2012 Oct; 15(5):473-80. PubMed ID: 22324859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estradiol affects extracellular leptin:adiponectin ratio in human breast tissue in vivo.
    Morad V; Abrahamsson A; Dabrosin C
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3460-7. PubMed ID: 24796929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant tamoxifen but not aromatase inhibitor therapy decreases serum levels of the Wnt inhibitor dickkopf-1 while not affecting sclerostin in breast cancer patients.
    Göbel A; Kuhlmann JD; Link T; Wimberger P; Browne AJ; Rauner M; Hofbauer LC; Rachner TD
    Breast Cancer Res Treat; 2017 Aug; 164(3):737-743. PubMed ID: 28526959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
    Tuxen MK; Nielsen DL; Lindberg H; Kamby C
    Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
    Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
    J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    J Clin Oncol; 2005 Aug; 23(22):5178-87. PubMed ID: 15998905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of tamoxifen in premenopausal and postmenopausal women with breast cancer.
    Lien EA; Anker G; Ueland PM
    J Steroid Biochem Mol Biol; 1995 Nov; 55(2):229-31. PubMed ID: 7495702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian hyperstimulation closely associated with resumption of follicular growth after chemotherapy during tamoxifen treatment in premenopausal women with breast cancer: a multicenter retrospective cohort study.
    Yamazaki R; Inokuchi M; Ishikawa S; Ayabe T; Jinno H; Iizuka T; Ono M; Myojo S; Uchida S; Matsuzaki T; Tangoku A; Kita M; Sugie T; Fujiwara H
    BMC Cancer; 2020 Jan; 20(1):67. PubMed ID: 31996163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
    Cheng WF; Lin HH; Torng PL; Huang SC
    Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
    Sawada S; Sato K; Kusuhara M; Ayaori M; Yonemura A; Tamaki K; Hiraide H; Mochizuki H; Ohsuzu F
    Acta Oncol; 2005; 44(2):134-41. PubMed ID: 15788292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.